Dr. Ron Dalman discusses a new clinical trial that has just started recruiting patients. LIMIT stands for Limiting AAA With Metformin. The popular diabetes drug has been shown to be negatively associated with the progression of abdominal aortic aneurysm (AAA) disease. Now with over population studies spanning two decades and several continents, the team at Stanford is ready to explore whether the same results can be achieved proactively.
Dr. Dalman is the Chidester Professor and Vice Chair of Clinical Affairs at Stanford Surgery. He is also a past president of the Society for Vascular Surgery.
For more information on the Clinical Trial, click here: https://clinicaltrials.gov/ct2/show/NCT04500756
If you would like to enroll in the study, contact Study Research Coordinator Lori McDonnell at lorimcd2@stanford.edu
view more